Glenmark Reports Strong Quarterly Profit Growth Driven by North America and Europe

Mumbai – Glenmark Pharmaceuticals reported a sharp rise in quarterly profit, supported by continued recovery in major international markets and stable demand across several key therapeutic segments.

The company said its second-quarter adjusted profit increased 72%, reflecting improved performance in North America and Europe and steady momentum in its domestic formulation business.

Glenmark posted a consolidated net profit of 6.1 billion rupees for the quarter ending September 30, compared with 3.54 billion rupees during the same period last year.

This upward trend marks one of its strongest quarterly improvements in recent years as product sales picked up across multiple regulated markets.

Total revenue from operations rose 76% to 60.47 billion rupees, with the company noting that both core business divisions and international subsidiaries contributed to the advance.

Executives said the quarter benefited from increased prescription trends, reduced supply chain pressures, and steady market access conditions.

The company’s India formulation business recorded secondary sales growth of 10.8%, signaling continued demand for essential therapies across chronic and acute care categories.

Industry data indicated the broader Indian pharmaceutical market expanded 7.3% in September, led by higher demand for cardiovascular, anti-diabetic, and anti-infective medicines.

Glenmark’s North America business reported net sales growth of 7.4%, aided by improved product availability and better market traction for key generics.

Similarly, sales in Europe climbed 8.5% as the company strengthened distribution and benefited from higher volumes in several established markets.

Industry analysts said Glenmark’s performance aligns with the recovery seen across large drugmakers following a sluggish year marked by pricing pressure, regulatory delays, and logistics challenges.

Peer companies such as Torrent Pharma also reported stronger profit numbers, while others like Mankind Pharma registered slower growth due to tax-related impacts on margins.

The company said it continues to focus on strengthening its core segments while exploring opportunities to expand its specialty and branded generics portfolio.

Management highlighted ongoing work to optimize operations, enhance research capabilities, and expand its manufacturing footprint across multiple geographies.

Market observers said Glenmark’s diversified portfolio and exposure to both developed and emerging markets have helped balance fluctuations in individual regions.

The company’s ability to sustain demand across chronic therapy areas has also supported revenue consistency amid shifting global conditions.

Pharmaceutical demand in India remained strong during the quarter, supported by rising lifestyle-related illnesses and increased uptake of maintenance medications.

Analysts expect broader market momentum to continue, driven by higher awareness, improved diagnosis rates, and wider access to healthcare services.

In overseas markets, Glenmark said it plans to enhance supply reliability and maintain regulatory compliance to support long-term commercial growth.

The company emphasized that North America and Europe will remain key focus regions given their market potential and stable business environments.

Glenmark added that it is preparing for new product launches and expansion in select specialty areas to strengthen its competitive position.

These initiatives, the company said, are part of a long-term strategy to diversify revenue and build a more resilient international business model.

The global pharmaceutical sector continues to face challenges including cost pressures, rising competition, and the need for continuous innovation.

Companies with strong research infrastructure and efficient supply networks, analysts say, are better positioned to navigate these industry headwinds.

Glenmark said it will continue monitoring global trends, policy developments, and market shifts to ensure stable performance across regions.

The company expects steady demand in its key therapy areas and remains cautiously optimistic about future quarters if current conditions hold.